Evommune, Inc. SEC filings EVMN

Evommune, Inc. has 138 filings in SEC EDGAR's recent list, going back to Jan 7, 2025. Its latest annual report, Form ARS, was filed on Apr 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Form Description Filed Period
424B3 Prospectus Nov 4, 2026 —
424B3 Prospectus Sep 9, 2026 —
424B3 Prospectus Aug 6, 2026 —
424B3 Prospectus Jun 29, 2026 —
424B3 Prospectus Jun 2, 2026 —
424B3 Prospectus May 7, 2026 —
424B3 Prospectus Apr 24, 2026 —
S-1 Registration statement Apr 17, 2026 —
S-8 Employee stock plan registration Mar 5, 2026 —
S-8 Employee stock plan registration Nov 7, 2025 —
424B4 Prospectus Nov 6, 2025 —
FWP Free writing prospectus Nov 6, 2025 —
FWP Free writing prospectus Oct 30, 2025 —
S-1/A Amended registration statement Oct 17, 2025 —
S-1 Registration statement Oct 9, 2025 —

Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
EVMN (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Palo Alto, CA
SEC filer status
, Emerging growth company
SEC CIK
2044725

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.